Introduction
Tyrosine phosphorylation of synaptic receptors and signaling molecules regulates synaptic activity [1, 2] . Considerable work has characterized the kinases involved in activity-dependent synaptic plasticity, with relatively less emphasis on the participating protein tyrosine phosphatases (PTPs). However, the identification and characterization of PTPs that participate in this process has begun and several are now known to be specifically expressed within the brain [3] .
One of these PTPs was named STEP (for STriatalEnriched tyrosine Phosphatase, also known as PTPN5), and recent evidence suggests it is important in synaptic plasticity. The past decade has seen considerable advances in our understanding of the function of STEP, as well as the identification of several target proteins by which STEP controls the development of synaptic plasticity. This review concentrates on three groups of proteins that STEP regulates: the mitogen-activated protein kinases (MAPKs), the tyrosine kinase Fyn, and the NMDA receptor complex. Tyrosine phosphorylation of one member of the MAPK family, the extracellular signal regulated kinase (ERK), is necessary for the expression and maintenance of synaptic plasticity in many brain regions [4] , and disruption of the ERK pathway leads to disruption of learning and memory. Activation of the Src family of non-receptor tyrosine kinases is also regulated by tyrosine phosphorylation. One function of these kinases is to phosphorylate NMDA receptors, thereby modulating their channel conductance properties and facilitating their movement to neuronal plasma membranes [2] . This potentiates their activity and is required for the induction of several forms of long-term potentiation (LTP) and long-term depression (LTD) [5, 6] . We discuss the properties of STEP that are necessary for its ability to regulate these three families of proteins and for its role in synaptic function, learning and CNS pathology.
Molecular properties of STEP STEP is specifically expressed within neurons of the CNS [7] . As its name indicates, the highest expression level is within the striatum [8] . However, more recent work has found that it is expressed at lower levels in multiple regions of the nervous system, including the neocortex, amygdala, hippocampus and embryonic spinal cord [9, 10] .
PTPs are broadly divided into the receptor-like and the non-receptor, intracellular phosphatases [3, 11] . Of the 100 PTPs identified in the human genome, STEP falls into a small subset of the non-receptor PTPs [12, 13] . Based on sequence homology, its closest relatives are HePTP and PTP-SL; these phosphatases are also expressed in a restricted fashion, with HePTP found only in leucocytes and PTP-SL enriched within the cerebellum [14] [15] [16] [17] .
STEP mRNA is alternatively spliced into two main variants (Figure 1) . The protein products are termed STEP 46 and STEP 61 based on their observed electrophoretic mobility [7, 18] . STEP 46 is cytosolic, whereas STEP 61 is membrane-bound and differs from STEP 46 by the presence of an extra 172 amino acids at its N-terminus (Figure 1 ). STEP 61 is not a plasma membrane spanning protein; rather, the N-terminal sequence targets STEP 61 to intracellular organelles including the endoplasmic reticulum (ER) and the postsynaptic density [9, 18, 19] . The orientation of STEP 61 on the ER is not currently known: the ability of STEP to regulate cytosolic proteins favors an orientation in which the catalytic domain faces the cytosolic compartment, although additional work is needed to clarify this point. Two additional alternatively spliced variants that lack an active phosphatase domain are expressed [20, 21] . The functions of these inactive variants are not known, although it is possible that in the absence of a catalytic domain, they might act as dominant-negative STEP isoforms that compete with the active isoforms for binding to substrates, through binding domains outside of the catalytic domain. In this review, we will concentrate on STEP 46 and STEP 61 because most of the work to date has studied the function of these two variants.
Both STEP 46 and STEP 61 have a C-terminal domain of 280 amino acids that contains a catalytic site with the consensus sequence [I/V]HCxAGxxR[S/T]G (Figure 1 ). Closer to the N terminal is a kinase-interacting motif (KIM) that is unique to STEP, HePTP and PTP-SL and is the binding site for members of the MAPK family. The 
